ArticlePharmacoEconomics - open2025
Carer Health-Related Quality of Life: A Review of Modelling Considerations in National Institute for Health and Care Excellence Technology Appraisals (2000-2023).
Article in PharmacoEconomics - open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCarer health-related quality of life (HRQoL) is increasingly used to support health technology assessments conducted by the National Institute for Health and Care Excellence (NICE). Modelling approaches and underlying rationales considered in NICE appraisals before the publication of the 'Spillovers in Health Economic Evaluation and Research' guidance were reviewed, alongside committee feedback and stated preferences.
methodsThe NICE website ( www.nice.org.uk ) was searched for final appraisal determinations (FADs) from 2000 to August 2023 that considered carer HRQoL. FADs were reviewed for an expression of whether carer HRQoL data were considered qualitatively (without formal economic modelling) or quantitatively (incorporated into cost-utility analyses) in decision-making. All related committee papers were retrieved for eligible submissions. Modelling approaches used were extracted as well as sources of carer HRQoL and reasons for including or excluding carer HRQoL from decision-making.
resultsNICE considered carer HRQoL data (sourced from observational studies, surveys, vignettes and clinical trials) for decision-making in 90% (44/49) of appraisals submitting such data (82% were considered quantitatively); carer HRQoL data were considered for decision-making in all appraisals involving rare diseases and paediatric populations. Three approaches (additive carer disutility [used in 90% of identified appraisals], additive carer utility [14%] and absolute carer utility [2%]) and two adjustments (application of carer/patient age/utility cap [20%] and carer/family bereavement [10%]) were identified for incorporating carer HRQoL. There was considerable variation in the implementation of these methods/adjustments.
conclusionsThis review of NICE appraisals identified three key methodologies and two adjustments for including carer HRQoL; the additive carer disutility approach was the most frequently used.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.